Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

09Sep

Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients

Portfolio News
Pittsburgh-based biotech company CytoAgents is launching into phase one of clinical trials this month on a drug designed to treat people with COVID-19 who develop serious respiratory distress when their immune system overreacts to the virus. Read more >>

Share this post

Related Posts

10Dec

RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station

RevBio, Inc., announced that an experiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard... read more
03Nov

In focus: Anchorage 6th grader sees clearly for the first time thanks to new tech, community support

Imagine the whole world around you is a blur. That was reality for an Anchorage sixth grader who is now... read more
19Aug

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced... read more
03Dec

The Boston Globe Names Wasabi Technologies a Top Place to Work for 2021

Wasabi Technologies, the hot cloud storage company, today announced it has been named one of the Top Places to Work... read more
23Mar

Respiratory Motion, Inc. is excited to announce FDA clearance for use of the ExSpiron™ 1Xi Minute Ventilation Monitor in Pediatric Patients

Respiratory Motion, Inc. reported today that FDA clearance was received for the newest version of its ExSpiron Minute Ventilation (MV)... read more
12Mar

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Frontiers in Immunology of a... read more
08Jul

FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors

The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors,... read more
15Jan

Cognoptix developing an Alzheimer’s disease test using the eye

Cognoptix Inc CEO Susanne Wilke sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The... read more
29Mar

Exclusive: Platelet Biogenesis Eyes Entering the Clinic, Doubling Employment This Year

The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant... read more
18Sep

USA-Based ZetrOZ Systems Selected by the National Institute of Aging to Present the Sustained Acoustic Medicine (SAM) Medical Product Portfolio to Global Healthcare Community

ZetrOZ Systems, a leading USA-based medical device manufacturer, was selected by the National Institute of Aging to present its product... read more